<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use 10% DEXTROSE INJECTION safely and effectively. See full prescribing information for DEXTROSE INJECTION.<br/>
      <br/>10% DEXTROSE injection, USP for intravenous use <br/>Initial U.S. Approval: 1940
</title>
   <effectiveTime value="20220210"/>
   <setId root="3b8f2692-4371-4f1a-95af-b41842131fdd"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC
</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="506719546" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi Deutschland GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-824" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-824" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="f633df88-2a23-4286-92c9-390a1cb58bbe"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20210930"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-824" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextrose<suffix/>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextrose Monohydrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE
</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DEXTROSE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="250" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-824-24" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-824-74" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190329"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-824-25" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="20" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-824-75" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190329"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-824-26" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-824-76" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190329"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209448" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190329"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="7e018662-2fe0-4c9e-a47c-6e80ae3baf27"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="85.000%" align="left"/>
                           <col width="15.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Dosage and Administration (<linkHtml href="#s4">2.1</linkHtml>, <linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s6">2.3</linkHtml>)
</td>
                                 <td align="right" valign="top">9/2021
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Contraindications (<linkHtml href="#s8">4</linkHtml>)
</td>
                                 <td align="right" valign="top">9/2021
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>, <linkHtml href="#s11">5.2</linkHtml>, <linkHtml href="#s12">5.3</linkHtml>, <linkHtml href="#s13">5.4</linkHtml>, <linkHtml href="#s14">5.5</linkHtml>, <linkHtml href="#s15">5.6</linkHtml>)
</td>
                                 <td align="right" valign="top">9/2021
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="189196e2-018b-41ed-8431-c949eee536a9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>10% Dextrose Injection is indicated as source of water and calories.
</paragraph>
               </text>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dextrose Injection is indicated as a source of water and calories. (<linkHtml href="#s2">1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="e19a7d7b-f9d5-47d7-afd9-8830649af351"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20211231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Only for intravenous infusion. (<linkHtml href="#s4">2.1</linkHtml>)
</item>
                           <item>See full prescribing information for information on preparation, administration, dosing considerations and instructions for use. (<linkHtml href="#s4">2.1</linkHtml>, <linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s6">2.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="8a21b517-e383-4d14-b59a-2ef26e9ba893"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>2.1 Important Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange"/>10% Dextrose Injection is intended for intravenous use.
</item>
                           <item>
                              <content styleCode="xmChange"/>Peripheral administration of 5% dextrose is generally acceptable, however, consider central vein when administering more than 5% dextrose or with an osmolarity of at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>.
</item>
                           <item>
                              <content styleCode="xmChange"/>Do not administer 10% Dextrose Injection simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis.
</item>
                           <item>
                              <content styleCode="xmChange"/>To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
</item>
                           <item>
                              <content styleCode="xmChange"/>Prior to infusion, visually inspect the diluted dextrose solution for particulate matter.  The solution should be clear and there should be no precipitates.  Do not administer unless solution is clear and container is undamaged.
</item>
                           <item>
                              <content styleCode="xmChange"/>Use of a final filter is recommended during administration of parenteral solutions, where possible.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="f955e238-58d7-494a-bd8d-dfd40460c2b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>2.2 Recommended Dosage
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>The choice of dextrose concentration, rate and volume depends on the age, weight, clinical and metabolic conditions  of the patient and concomitant therapy. Electrolyte supplementation may be indicated according to the clinical needs of the patient.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>The administration rate should be governed, especially for premature infants with low birth weight, during the first few days of therapy, by the patient's tolerance to dextrose.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Increase the infusion  rate gradually as indicated by frequent monitoring  of blood glucose concentrations <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>), Use in Specific Populations (<linkHtml href="#s24">8.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="20bf1849-ed82-4c38-a145-2a2b24ed0cd7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>2.3 Instructions for Use
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Check flexible container solution composition, lot number, and expiry date. Prior to administration, visually inspect for particulate matter and discoloration.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>The intact port caps provides visual tamper evidence. Do not use if a port cap is prematurely removed. Do not remove solution container from its overwrap until immediately before use. Use sterile equipment and aseptic technique.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="underline">To Open</content>
                        </paragraph>
                        <content styleCode="xmChange"/>
                        <list listType="ordered" styleCode="Arabic">
                           <item>
                              <content styleCode="xmChange"/>Place the solution container on a clean, flat surface. Using the pre-cut corner tabs, peel open the overwrap and remove solution container.
</item>
                           <item>
                              <content styleCode="xmChange"/>Check the solution container for leaks by squeezing firmly. If leaks are found, or if the seal is not intact, discard the solution.
</item>
                           <item>
                              <content styleCode="xmChange"/>Do not use if the solution is cloudy or a precipitate is present.
</item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="underline">To Add Medication</content>
                        </paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>
                              <content styleCode="xmChange"/>Identify WHITE Additive Port with arrow pointing toward container.
</item>
                           <item>
                              <content styleCode="xmChange"/>Immediately before injecting additives, break off WHITE Additive Port Cap with the arrow pointing toward container.
</item>
                           <item>
                              <content styleCode="xmChange"/>Hold base of WHITE Additive Port horizontally.
</item>
                           <item>
                              <content styleCode="xmChange"/>Insert needle (18 to 23 gauge) horizontally through the center of WHITE Additive Port's septum and inject additives.
</item>
                           <item>
                              <content styleCode="xmChange"/>Mix container contents thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
</item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="underline">Preparation for Administration</content>
                        </paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>
                              <content styleCode="xmChange"/>Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from container.
</item>
                           <item>
                              <content styleCode="xmChange"/>Use a non-vented infusion set or close the air-inlet on a vented set.
</item>
                           <item>
                              <content styleCode="xmChange"/>Close the roller clamp of the infusion set.
</item>
                           <item>
                              <content styleCode="xmChange"/>Hold the base of BLUE Infusion Port.
</item>
                           <item>
                              <content styleCode="xmChange"/>Insert spike through BLUE Infusion Port by rotating wrist slightly until the spike is inserted.
</item>
                           <item>
                              <content styleCode="xmChange"/>Suspend solution container from hanger hole
</item>
                           <item>
                              <content styleCode="xmChange"/>For Single Use Only. Discard unused portion.
</item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="bold">NOTE:</content> See full directions accompanying administration set.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="bold">WARNING: Do not use flexible container in series connections.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="f0cffe06-a633-47fa-b88c-cbdc7ff8b09b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>10% Dextrose Injection, USP is a clear, sterile, non-pyrogenic solution of dextrose in single-dose flexible plastic containers
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>10% (0.1 grams/mL):  10 grams of dextrose hydrous per 100 mL in flexible plastic containers:  250 mL, 500 mL, and 1000 mL
</item>
                  </list>
               </text>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>10% (0.1 grams/mL): 10 grams of dextrose hydrous per 100 mL in flexible containers: 250 mL, 500 mL, and 1000 mL. (<linkHtml href="#s7">3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="8a4e93b8-b6f3-4f93-8979-7f9ec90f5b51"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>The use of Dextrose Injection is contraindicated in patients with:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange"/>Clinically  significant  hyperglycemia  <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>.
</item>
                     <item>
                        <content styleCode="xmChange"/>Known hypersensitivity  to dextrose <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>.
</item>
                  </list>
               </text>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Clinically significant hyperglycemia. (<linkHtml href="#s8">4</linkHtml>)
</item>
                           <item>Known hypersensitivity to dextrose. (<linkHtml href="#s8">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="f16a9227-6f9d-486a-a44f-190c2a87dda9"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hyperglycemia or Hyperosmolar Hyperglycemic State</content>: Monitor blood glucose and administer insulin as needed. (<linkHtml href="#s10">5.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Monitor for signs and symptoms and discontinue infusion if reactions occur. (<linkHtml href="#s11">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Vein Damage and Thrombosis</content>: Consider central vein when administering more than 5% dextrose or with an osmolarity of at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain. (<linkHtml href="#s5">2.2</linkHtml>, <linkHtml href="#s12">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Hyponatremia</content>: Avoid in patients with or at risk for hyponatremia.  If use cannot be avoided, monitor serum sodium concentrations. (<linkHtml href="#s13">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Electrolyte Imbalance and Fluid Overload</content>: Avoid in patients with or at risk for fluid and/or solute overloading.  If use cannot be avoided, monitor daily fluid balance, electrolyte concentrations, and acid-base balance, as needed and especially during prolonged use. (<linkHtml href="#s14">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Refeeding Syndrome</content>: Monitor severely undernourished patients and slowly increase nutrient intake. (<linkHtml href="#s15">5.6</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="dce8562e-7df0-449c-885a-54c11c27dba1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>The use of dextrose infusions in patients with impaired glucose tolerance may worsen hyperglycemia.  Administration of dextrose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>)]</content>. Patients with underlying CNS disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Monitor blood glucose levels and treat hyperglycemia to maintain levels within normal limits while administering 10% Dextrose Injection. Insulin may be administered or adjusted to maintain optimal blood glucose levels during 10% Dextrose Injection administration.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="04b11011-3afd-4121-b5e5-3a5263f017c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.2 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>Hypersensitivity and infusion reactions, including anaphylaxis, have been reported with 10% Dextrose Injection <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s16">6</linkHtml>)]</content>. Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="56be5bb2-9b3b-4ca2-84b8-c42e1fea1e75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Vein Damage and Thrombosis
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Peripheral administration of 5% Dextrose Injection is generally acceptable, however,  consider central vein when administering more than 5% dextrose or with an osmolarity of ≥ at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s4">2.1</linkHtml>)]</content>.The infusion of hypertonic solutions into a peripheral vein may result in vein irritation,  vein damage, and/or thrombosis. The primary complication  of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="21f22497-b534-485b-829c-c52340b4f607"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.4 Hyponatremia
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>10% Dextrose Injection is a hypertonic solution <content styleCode="italics">[see Description, <linkHtml href="#t1">Table 1</linkHtml> (<linkHtml href="#s27">11</linkHtml>)]</content>. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization.  Monitoring of serum sodium is particularly important for hypotonic fluids.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Depending on the tonicity of the solution, the volume and rate of infusion, and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances, most importantly hypo- or hyperosmotic hyponatremia. Monitor serum sodium to minimize the risk of hyponatremia.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>The risk for hyponatremia is increased in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia, and in patients treated with medications that increase the risk of hyponatremia (such as diuretics, certain antiepileptic and psychotropic medications). Close clinical monitoring may be warranted.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Acute hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting.  Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury. Patients at increased risk for developing complications of hyponatremia, such as hyponatremic encephalopathy include pediatric patients; women, in particular, premenopausal women; patients with hypoxemia; and in patients with underlying central nervous system disease <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s24">8.4</linkHtml>, <linkHtml href="#s25">8.5</linkHtml>)]</content>.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Avoid Dextrose Injection in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications.  Brain adaptations reducing risk of cerebral edema make the brain vulnerable to injury when chronic hyponatremia is too rapidly corrected, which is known as osmotic demyelination syndrome (ODS). To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>High volume infusion must be used with close monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatremia.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="f7dcb717-8897-4afd-915d-499f2a6eceb6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.5 Electrolyte Imbalance and Fluid Overload
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Depending on the volume and rate of infusion,  the patient's underlying clinical condition and capability to metabolize dextrose, intravenous administration of 10% Dextrose Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, (including  hypoosmotic hyponatremia), overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution.  The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Avoid Dextrose Injection in patients with or at risk for fluid and/or solute overloading.  If use cannot be avoided, monitor fluid balance, blood electrolyte levels, concentration of glucose, acid-base balance, correct fluid and electrolyte imbalances during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation and acid-base balance as needed and especially during prolonged  use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load. Patients at increased risk for developing hyponatremic encephalopathy include pediatric patients; elderly patients, women, in particular premenopausal women; patients with hypoxemia; and patients with underlying CNS disease <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s24">8.4</linkHtml>, <linkHtml href="#s25">8.5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="3b1169a6-2194-49ba-86ba-62391b60e793"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.6 Refeeding Syndrome
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Refeeding severely undernourished  patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intake.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="44ce0458-aa38-404d-818f-70c8067892a6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of dextrose injection were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.
</paragraph>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hyperglycemia and hyperosmolar hyperglycemic state <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Hypersensitivity Reactions</content>: anaphylaxis, pruritus, bronchospasm, cyanosis, angioedema, hypotension, pyrexia, chills, and rash <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Infusion Site Reactions</content>: infusion site phlebitis, infusion site erythema, vein damage and thrombosis, and infusion site thrombophlebitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hyponatremia and hyponatremic encephalopathy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>
                     </item>
                     <item>Electrolyte imbalance, fluid overload and hypervolemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>)]</content>
                     </item>
                     <item>Refeeding syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)]</content>
                     </item>
                     <item>Pulmonary vascular precipitates
</item>
                  </list>
               </text>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions are, hyperglycemia, hypersensitivity reactions, hyponatremia, infection both systemic and at the injection site, vein thrombosis or phlebitis, and electrolyte imbalance. (<linkHtml href="#s16">6</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="810ed212-3355-4982-8785-0644327ebb6a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance</content>: Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance. (<linkHtml href="#s18">7.1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s18">
                     <id root="31f82217-133c-4325-b4cf-2094086ee462"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance
</title>
                     <text>
                        <paragraph>Dextrose Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>, <linkHtml href="#s13">5.4</linkHtml>, <linkHtml href="#s14">5.5</linkHtml>)]</content>. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="845d5a74-a00b-4a0e-b650-0f1df438fd22"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20210930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pediatric Use</content>: Increased risk of hypoglycemia/hyperglycemia; monitor serum glucose concentrations. (<linkHtml href="#s24">8.4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s20">
                     <id root="f170838b-e8bf-41b9-81f4-6c93ab23f774"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20210930"/>
                     <component>
                        <section ID="s21">
                           <id root="a9295510-393a-4448-a451-3ce9bf0cfd2a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Appropriate administration of 10% Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations.  Animal reproduction studies have not been conducted with injectable dextrose solutions.
</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20210930"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="1983df19-1884-4302-945f-dcc18f2ae5a4"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20210930"/>
                     <component>
                        <section ID="s23">
                           <id root="db390cd3-38f6-4cc0-9686-3d6bb6af18dc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of 10% Dextrose Injection to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for 10% Dextrose Injection and any potential adverse effects on the breastfed infant from 10% Dextrose Injection or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20210930"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="ad460391-1ab8-4414-94d7-9bb816850700"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety profile of 10% Dextrose Injection in pediatric patients is similar to adults.
</paragraph>
                        <paragraph>Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long-term adverse effects.
</paragraph>
                        <paragraph>Closely monitor plasma electrolyte concentrations in pediatric patients who may have impaired ability to regulate fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of 10% Dextrose Injection may result in increased serum osmolality and risk of intracerebral hemorrhage.
</paragraph>
                        <paragraph>Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="7e4d924e-e39f-47bd-b82e-57b960757309"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Clinical studies of 10% Dextrose Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients are at increased risk of developing hyponatremia  as well as for developing hyponatremic encephalopathy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</paragraph>
                        <paragraph>Dextrose is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="9e9ea6cf-4904-41bb-8dfb-b1285dbff8e5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>An increased infusion rate of 10% Dextrose Injection or administration of dextrose solutions can cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>, <linkHtml href="#s14">5.5</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal. Discontinue infusion, reduce dose and institute appropriate corrective measures such as administration  of exogenous insulin.
</paragraph>
                  <paragraph>Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to CNS, respiratory and cardiovascular systems.
</paragraph>
                  <paragraph>If over-exposure occurs, call your Poison Control Center at 1-800-222-1222  for current information  on the management of poisoning  or overdosage.
</paragraph>
               </text>
               <effectiveTime value="20210930"/>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="892d2272-6727-4f81-ba95-c0b82edbd506"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>10% Dextrose Injection, USP is a sterile, non-pyrogenic solution for fluid replenishment and caloric supply in single dose containers for intravenous administration.
</paragraph>
                  <paragraph>The solution contains no bacteriostatic, antimicrobial agent or added buffer and is intended only for use as a single-dose injection.  The pH range is 4.0 (3.2 to 6.5)
</paragraph>
                  <table ID="t1" width="100%">
                     <caption>Table 1. Contents and Characteristics of Dextrose Injection 10%, USP
</caption>
                     <col width="20.160%" align="left"/>
                     <col width="15.400%" align="left"/>
                     <col width="27.920%" align="left"/>
                     <col width="16.360%" align="left"/>
                     <col width="20.160%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="5" align="left" valign="top">
                              <paragraph styleCode="footnote">*Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Fill Volume</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Amount of Dextrose Hydrous per Container</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">kcal* per Container</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Osmolarity</content>
                              <br/>
                              <content styleCode="bold">(mOsmol per liter)</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="3" align="center" valign="top" styleCode="Botrule Lrule Rrule">Dextrose Injection<br/>10%, USP<br/>(0.1 grams/mL)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">250 mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">25 grams
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">85
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">505
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Rrule">500 mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">50 grams
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">170
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">505
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Rrule">1000 mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">100 grams
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">340
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">505
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Dextrose, USP is chemically designated D-glucose, monohydrate (C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> • H<sub>2</sub>O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  </paragraph>
                  <paragraph>Water for Injection, USP is chemically designated H<sub>2</sub>O.
</paragraph>
                  <paragraph>Dextrose is derived from corn.
</paragraph>
                  <paragraph>The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (<content styleCode="bold">free</content>
                     <content styleCode="italics">flex</content>® bag).  The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.
</paragraph>
                  <paragraph>The flexible container is a closed system, and air is prefilled in the container to facilitate drainage. The container does not require entry of external air during administration. 
</paragraph>
                  <paragraph>The container has two ports: one is the administration outlet port for attachment of an intravenous administration set and the other port has a medication site for addition of supplemental medication <content styleCode="italics">([see Instructions for Use (<linkHtml href="#s6">2.3</linkHtml>)]</content>). The primary function of the overwrap is to protect the container from the physical environment.
</paragraph>
               </text>
               <effectiveTime value="20210930"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dex0s-0002-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="0d6f6105-48b1-480f-b5e3-aa7d1b23eba5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20210930"/>
               <component>
                  <section ID="s29">
                     <id root="4c83284d-f5ac-4132-8abb-3285d2e576af"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Dextrose is oxidized to carbon dioxide  and water, yielding  energy.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="d1379e46-e954-455f-bbca-caeafa1eb16c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>10% Dextrose Injection, USP is supplied in single dose flexible plastic containers as follows:
</paragraph>
                  <table width="100%">
                     <col width="22.375%" align="left"/>
                     <col width="22.425%" align="left"/>
                     <col width="29.200%" align="left"/>
                     <col width="26.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Product Number</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Unit of Sale</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Each</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">824174
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">63323-824-74<br/>Package of 30<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">25 grams per 250 mL (100 mg per mL)
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 63323-824-24<br/>One 250 mL<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">824175
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">63323-824-75<br/>Package of 20<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">50 grams per 500 mL (100 mg per mL)
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 63323-824-25<br/>One 500 mL<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">824176
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">63323-824-76<br/>Package of 10<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">100 grams per 1,000 mL (100 mg per mL)
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">NDC 63323-824-26<br/>One 1000 mL<br/>
                              <content styleCode="bold">free</content>
                              <content styleCode="italics">flex</content>
                              <sup>®</sup> bag
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat.
</paragraph>
               </text>
               <effectiveTime value="20210930"/>
               <component>
                  <section ID="s31">
                     <id root="4739f98c-5af2-4a84-9c9e-9639b18a94cb"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">STORE AT: 20°</content> to <content styleCode="bold">25</content>°C (<content styleCode="bold">68°</content> to <content styleCode="bold">77°</content>F) [see USP Controlled Room Temperature]; brief exposure up to 40°C/104°F does not adversely affect the product. Keep from freezing.
</paragraph>
                        <paragraph>The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.
</paragraph>
                     </text>
                     <effectiveTime value="20210930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="2c6d1dcf-049a-4831-931f-ddac77310c3c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Inform patients, caregivers, or home healthcare providers of the following  risks of 10% Dextrose Injection:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hyperglycemia and hyperosmolar hyperglycemic  state <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity  reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>
                     </item>
                     <item>Vein damage and thrombosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hyponatremia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.4</linkHtml>)]</content>
                     </item>
                     <item>Electrolyte imbalance and fluid overload <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.5</linkHtml>)]</content>
                     </item>
                     <item>Refeeding syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.6</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph>Manufactured for:
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f02" referencedObject="mm02"/>
                  </paragraph>
                  <paragraph>Lake Zurich, IL  60047
</paragraph>
                  <paragraph>Made in Germany
</paragraph>
                  <paragraph>www.fresenius-kabi.com/us<br/>451516B
</paragraph>
               </text>
               <effectiveTime value="20211231"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Fresenius Kabi Logo
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dex0s-0002-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s33">
               <id root="ace76c42-0e59-4806-b8a1-7d00a8545af0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 10% Dextrose Bag Label<br/>
                     </content>NDC 63323-824-24<br/>
                     <content styleCode="bold">free
</content>
                     <content styleCode="italics">flex
</content>
                     <sup>®</sup>                                         <content styleCode="bold">250 mL<br/>10% Dextrose Injection, USP<br/>25 grams per 250 mL</content> (100 mg per mL)<br/>For intravenous use.               Rx only
</paragraph>
                  <br/>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20161112"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>bag
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dex0s-0002-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s34">
               <id root="a9cc20d4-f6fb-4ecc-9934-356decc33576"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 10% Dextrose Bag Label<br/>
                     </content>NDC 63323-824-25<br/>
                     <content styleCode="bold">free
</content>
                     <content styleCode="italics">flex
</content>
                     <sup>®</sup>                                         <content styleCode="bold">500mL<br/>10% Dextrose Injection, USP<br/>50 grams per 500 mL</content> (100 mg per mL)<br/>For intravenous use.               Rx only
</paragraph>
                  <br/>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM5"/>
                  <br/>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20161112"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>bag
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dex0s-0002-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="0ecf24fe-f8a9-484f-8aad-584544921251"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 10% Dextrose Bag Label<br/>
                     </content>NDC 63323-824-26<br/>
                     <content styleCode="bold">free
</content>
                     <content styleCode="italics">flex
</content>
                     <sup>®</sup>                                         <content styleCode="bold">1,000mL<br/>10% Dextrose Injection, USP<br/>100 grams per 1,000 mL</content> (100 mg per mL)<br/>For intravenous use.               Rx only
</paragraph>
                  <br/>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM6"/>
                  <br/>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20161112"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>bag
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="dex0s-0002-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>